OmniCyte is a private, preclinical biotech founded in 2018, developing a novel platform of recombinant targeted immunomodulators (co-stimulators) for cancer therapy. The company boasts a scientifically distinguished team and advisory board with deep expertise in oncology and immunology, including pioneers of the PD-1/PD-L1 field. It is initially targeting ovarian cancer and small cell lung cancer, with funding from grants, state innovation funds, and angel investors.
Oncology
Technology Platform
Proprietary Immuno-Oncology Platform for developing recombinant targeted immunomodulators (co-stimulators) designed to precisely activate the immune system against cancer.
Funding History
1
Total raised:$2.5M
Seed$2.5MUndisclosed
Opportunities
The significant unmet need in deadly cancers like ovarian and small cell lung cancer presents a clear regulatory and commercial pathway for a successful therapy.
The company's prestigious scientific network, including PD-1 pioneer Lieping Chen, provides exceptional validation and partnership potential.
The platform's applicability to multiple cancer types offers long-term pipeline expansion and value creation opportunities.
Risk Factors
The novel co-stimulator platform is at a high-risk, preclinical stage with no guarantee of clinical success.
The company faces intense competition from large, well-funded players in the immuno-oncology space.
As a pre-revenue private company, it is dependent on securing additional grant or venture funding to advance its programs.
Competitive Landscape
OmniCyte operates in the highly competitive field of immuno-oncology, competing directly with large pharmaceutical companies and numerous biotechs developing next-generation immunomodulators. Its specific focus on co-stimulatory pathways places it against other companies targeting receptors like 4-1BB, OX40, and GITR. Success will require demonstrating superior efficacy or safety compared to these existing approaches.
